NO20006086L - Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein - Google Patents

Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein

Info

Publication number
NO20006086L
NO20006086L NO20006086A NO20006086A NO20006086L NO 20006086 L NO20006086 L NO 20006086L NO 20006086 A NO20006086 A NO 20006086A NO 20006086 A NO20006086 A NO 20006086A NO 20006086 L NO20006086 L NO 20006086L
Authority
NO
Norway
Prior art keywords
homocysteine
reactive protein
procedure
reducing levels
levels
Prior art date
Application number
NO20006086A
Other languages
English (en)
Other versions
NO20006086D0 (no
Inventor
Pamela Wang Anderson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20006086L publication Critical patent/NO20006086L/no
Publication of NO20006086D0 publication Critical patent/NO20006086D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører en fremgangsmåte for å senke nivåer av homocystein og/eller C-reaktivt protein hos mennesker omfattende å administrere til et pattedyr som har behov for dette en effektiv mengde av en forbindelse med formel I eller et farmasøytisk salt eller solvat derav.
NO20006086A 1998-06-17 2000-11-30 Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein NO20006086D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8960198P 1998-06-17 1998-06-17
PCT/US1999/012604 WO1999065306A1 (en) 1998-06-17 1999-06-04 Methods for reducing levels of homocysteine and c-reactive protein

Publications (2)

Publication Number Publication Date
NO20006086L true NO20006086L (no) 2000-11-30
NO20006086D0 NO20006086D0 (no) 2000-11-30

Family

ID=22218549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006086A NO20006086D0 (no) 1998-06-17 2000-11-30 Fremgangsmåte for å redusere nivåer av homocystein og C- reaktive protein

Country Status (18)

Country Link
US (1) US6353003B1 (no)
EP (1) EP0966965A1 (no)
JP (1) JP2002518296A (no)
KR (1) KR20010052947A (no)
CN (1) CN1305342A (no)
AU (1) AU753035B2 (no)
BR (1) BR9911224A (no)
CA (1) CA2333384A1 (no)
EA (1) EA200100049A1 (no)
HR (1) HRP20000860A2 (no)
HU (1) HUP0102383A3 (no)
IL (1) IL138915A0 (no)
NO (1) NO20006086D0 (no)
PL (1) PL344841A1 (no)
SK (1) SK18802000A3 (no)
TR (1) TR200003713T2 (no)
WO (1) WO1999065306A1 (no)
ZA (1) ZA200005884B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585507A2 (en) * 2003-01-06 2005-10-19 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
WO2004093882A1 (ja) * 2003-04-18 2004-11-04 Advanced Medicine Research Institute 眼に適用する疾患治療剤
US20070003600A1 (en) * 2003-06-11 2007-01-04 Carolyn Moore Methods for reducing c-reactive protein
TWI386204B (zh) * 2008-04-10 2013-02-21 Mitsubishi Tanabe Pharma Corp 高半胱胺酸合成酶抑制劑

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
CZ286365B6 (cs) 1993-12-21 2000-03-15 Eli Lilly And Company Farmaceutický prostředek pro inhibici LDL oxidace a atherosklerosy
US5476862A (en) 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法
US6069175A (en) 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6025373A (en) 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
US6103740A (en) 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts

Also Published As

Publication number Publication date
TR200003713T2 (tr) 2001-04-20
HRP20000860A2 (en) 2001-10-31
HUP0102383A3 (en) 2003-01-28
EP0966965A1 (en) 1999-12-29
CN1305342A (zh) 2001-07-25
ZA200005884B (en) 2001-10-22
WO1999065306A1 (en) 1999-12-23
PL344841A1 (en) 2001-11-19
KR20010052947A (ko) 2001-06-25
JP2002518296A (ja) 2002-06-25
IL138915A0 (en) 2001-11-25
AU753035B2 (en) 2002-10-03
CA2333384A1 (en) 1999-12-23
EA200100049A1 (ru) 2001-06-25
NO20006086D0 (no) 2000-11-30
HUP0102383A2 (hu) 2002-01-28
SK18802000A3 (sk) 2001-09-11
AU4819299A (en) 2000-01-05
US6353003B1 (en) 2002-03-05
BR9911224A (pt) 2001-02-20

Similar Documents

Publication Publication Date Title
NO20025450D0 (no) Ny farmasöytisk sammensetning
FI970825L (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
BR9811099A (pt) Inibidores de urocinase
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DE60114994D1 (de) Blutplättchen-adp-rezeptor-inhibitoren
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
FI972781L (fi) Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä
NO961326D0 (no) Inhibitorer av
DK1682074T3 (da) Præparater og fremgangsmåder til sund graviditet
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
SE9800836D0 (sv) New Compounds
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
IS6207A (is) Indazol efnasambönd og lyfjafræðilegar blöndur til að hindra prótín kínasa og aðferð til að nota þau
BRPI0409417A (pt) método para usar um composto, composto, e, composição
DK0950057T3 (da) 3-pyridylenantiomerer og deres anvendelse som analgetika
BR0110530A (pt) Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina
NO20000231L (no) Dolastatin-15-derivater
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
NO940809D0 (no) Farmasöytisk preparat inneholdende en uricosurisk og en eksitatorisk aminosyre-antagonist
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application